Article: Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting.(Clinical report)

Article: Neurocrine Biosciences Reports Positive Results From Second ...
PR Newswire;  April 21, 2003 ;     700+ words ... ... from the Company's second Phase III clinical trial with an ... parallel group, multicenter Phase III clinical trial designed ... primary endpoint was Latency to Persistent Sleep (LPS) as measured objectively ... results previously reported in Phase II studies in patients suffering ...

Article: Neurocrine Biosciences Announces Second Presentation of Indiplon ...
PR Newswire;  May 22, 2003 ;     700+ words ... ... abstract reporting data from a Phase II clinical trial with indiplon ... parallel group, dose-response Phase II clinical study with two ... primary endpoint was Latency to Persistent Sleep (LPS) as measured objectively ... blind, three-way crossover Phase I clinical study in ten healthy ...

Article: Neurogen Commences Phase II Clinical Trial in Chronic ...
PR Newswire;  October 30, 2006 ;     700+ words ... ... that it has commenced a Phase II clinical trial in ... in time to onset of persistent sleep and sleep maintenance ... s portfolio. The Phase II clinical trial is ... announced results from Phase II human testing in ... reducing time to onset of persistent sleep in a well established ...

Article: Neurogen Announces Positive Phase II Clinical Trial ...
PR Newswire;  May 11, 2006 ;     700+ words ... ... line results of Phase II human testing ... time to onset of persistent sleep in a well established ... time to onset of persistent sleep versus placebo ... reducing Latency to Persistent Sleep (LPS) at all ... endpoint in this Phase II study in such ...

Article: Somaxon Pharmaceuticals' SILENOR(TM) Demonstrates Positive ...
PR Newswire;  October 23, 2006 ;     700+ words ... ... Endpoint of Latency to Persistent Sleep (LPS) Demonstrates ... Represents Second Phase 3 Clinical Trial of ... from the company's Phase 3 clinical trial evaluating ... this trial, Latency to Persistent Sleep (LPS), a measure ... sleep maintenance. This Phase 3 trial was a randomized ...

Article: Neurocrine Biosciences Ramps Up Phase III Clinical Trials ...
PR Newswire;  March 19, 2002 ;     700+ words ... ... controlled, parallel group Phase III clinical trial to ... endpoint will be Latency to Persistent Sleep (LPS) as measured ... initiate its fourth Phase III clinical trial in ... endpoint of Latency to Persistent Sleep (LPS) as measured ... in the U.S. "Our Phase III clinical program ...

Article: Neurogen Commences Sleep Maintenance Phase II Clinical ...
PR Newswire;  December 20, 2006 ;     700+ words ... ... complements the earlier Phase II clinical trial the ... October 30, 2006. The Phase II clinical trial announced ... measured by latency to persistent sleep (LPS) and additional ... announced results from Phase II human testing in ... reducing time to onset of persistent sleep in a ...